Skip to main content

Peter Danias has extensive experience and regularly represents clients in matters relating to the pre-merger notification requirements in the US under the Hart-Scott-Rodino Antitrust Improvements Act (the “Act”) and throughout the world. Mr. Danias also advises clients with regard to permissible pre-clearance and pre-closing activities as well as information sharing. In addition, he counsels clients who may have inadvertently failed to file under the Act. He regularly represents purchasers and sellers, including private equity firms, in many complex transactions in a variety of industries including life sciences, healthcare, defense, energy, finance, technology, software, aviation, construction, chemical, automotive, food and beverage, retail and internet stores, payroll, shipping, education, and apparel.

Mr. Danias also advises on the relevant aspects of broker-dealer regulation and has significant experience advising clients with respect to the formation, acquisition, and sale of US broker-dealers as well as establishing chaperoning arrangements under Rule 15a-6. He also represents clients before the New York Stock Exchange, NYSE MKT, and the various NASDAQ Stock Markets and works regularly with the staffs of these self-regulatory organizations.

He works on a variety of both public and private financings and also concentrates on matters involving compliance with state securities laws where he secures approvals for various types of transactions. He is often called upon to assist in structuring transactions.


  • Alcon Inc. in its acquisition of Kala Pharmaceutical’s commercial portfolio and related intellectual property assets. The assets included EYSUVIS, the first and only US FDA-approved medicine for the short-term treatment of the signs and symptoms of dry eye disease, and INVELTYS, a twice-a-day corticosteroid for the treatment of post-operative inflammation and pain following ocular surgery.
  • Fresenius Kabi USA LLC, a subsidiary of multinational global healthcare company Fresenius Kabi AG, in its acquisition of Ivenix Inc., a venture-backed smart infusion pump developer. The purchase price was a combination of $240 million upfront payment and milestone payments linked to achievements of commercial and operating targets.
  • The sale of Prosidyan, Inc., a developer of proprietary fiber-based bioactive glass orthobiologics products used as a bone graft substitute, to a subsidiary of Johnson and Johnson.
  • Thermo Fisher’s $17.4 billion acquisition of clinical research provider PPD, Inc.
  • Novartis, with respect to the in-license of global rights to ensovibep from Molecular Partners AG. Ensovibep is a DARPin antiviral therapeutic candidate to treat COVID-19.
  • Novartis in acquiring Food and Drug Administration priority review vouchers.
  • Novartis in the sale to Mylan N.V. of its global cystic fibrosis products, including the TOBI® Podhaler and TOBI® solution, for $463 million.
  • Sandoz in its $1.525 billion acquisition of specialty dermatology generics company Fougera Pharmaceuticals from a consortium of private equity funds led by Nordic Capital DLJ Merchant Banking (a Credit Suisse affiliate) and Avista Capital Partners.
  • Sanofi in a long-term research collaboration with Kymera Therapeutics to discover, develop and commercialize first-in-class protein degrader therapies for patients with immune-inflammatory diseases.
  • Celgene Corporation’s proposed acquisition of Nimbus Lakshmi, Inc., a developer of Tyk2 inhibitors for immunology and inflammation.



  • J.D., Southwestern University School of Law, 1982
  • B.A., Fordham University, 1979


  • New York
  • New Jersey
  • U.S. Tax Court


  • Member, American Bar Association Antitrust Section, Mergers and Acquisitions Committee
  • Member, American Bar Association Section of Business Law, Committee on State Regulation of Securities